Samsung BioLogics moves into the green in 2017

Home > Business > Industry

print dictionary print

Samsung BioLogics moves into the green in 2017

Samsung BioLogics, a biopharmaceutical unit of Korea’s top conglomerate, Samsung Group, posted an operating income last year, shifting from a loss a year earlier, the company said Wednesday.

The total reached 63 billion won ($60 million) in 2017, compared to a 30.4 billion won loss reported a year earlier, the company said in a regulatory filing.

Sales also jumped 56.1 percent on-year to 459.8 billion won for the whole of last year, the company said.

Samsung BioLogics manufactures products for pharmaceutical brands such as Bristol-Myers Squibb and Roche Holding.

More in Industry

DSME fined ₩15.3 billion for mistreating subcontractors

Hyundai, Naver to work together on connected car systems

SK Telcom merges two security services subsidiaries

KDB requests sit-down with Asiana unions about takeover

Are you Taycan to me?

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now